Stock Update: Eli Lilly & Company (NYSE:LLY) – U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®

[PR Newswire] – U-200), a pre-filled pen containing a concentrated formulation of Lilly’s rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, . . . → Read More: Stock Update: Eli Lilly & Company (NYSE:LLY) – U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen® Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Second-Quarter 2015 Dividend Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Market Update (NYSE:LLY): FDA approves Boehringer-Lilly drug for type-2 diabetes patients